Fig. 5: RBCK1 controls p53 protein levels and expression of p53 target genes.
From: RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma
a RBCK1 depletion increases p53 protein levels and p53 target genes using two different siRNA oligos. siControl was compared to siRBCK1 #1 group/siRBCK1 #2 group separately. After 48 h, p53 and RBCK1 levels were determined by Western blot analysis and RNA was prepared for detecting endogenous p53 target genes, P21, P53INP1 and BTG2 by qPCR. Shown are the results from three experiments. P value for siRBCK1 versus siControl. GAPDH was used as the internal control. **P < .01; ***P < .001. b RBCK1 depletion increases p53 protein levels and p53 target genes using two different siRNA oligos. siControl was compared to siRBCK1 #1 group/siRBCK1 #2 group separately. After 48 h, p53 and RBCK1 levels were determined by Western blot analysis and RNA was prepared for detecting endogenous p53 target genes, P21, P53INP1 and BTG2 by qPCR. Shown are the results from three experiments. P value for siRBCK1 versus siControl. GAPDH was used as the internal control. **P < .01; ***P < .001. c RBCK1 depletion increases p53 protein levels and p53 target genes under the treatment of cisplatin. After 48 h of transfection, cells were treated with 10 μM cisplatin or vehicle. p53 and RBCK1 levels were determined by Western blot analysis. Each experiment was repeated three times and GAPDH was used as the internal control. The expression levels of the endogenous p53 target genes, P21, P53INP1 and BTG2 were determined by qPCR. 48 h after transfection, cells were treated with 10 μM cisplatin or vehicle for 6 h and RNA was prepared. Shown are the results from the triplicate experiments. P value for siRBCK1 versus siControl. siControl were compared to sRBCK1 group; in cisplatin treated samples, siControl was compared to the siRBCK1 group separately. *P < .05; **P < .01; ***P < .001. d RBCK1 depletion increases p53 protein levels and p53 target genes under the treatment of cisplatin. 48 h after transfection, cells were treated with 10 μM cisplatin or vehicle. p53 and RBCK1 levels were determined by Western blot analysis. Each experiment was repeated three times and GAPDH was used as the internal control. The expression levels of the endogenous p53 target genes, P21, P53INP1 and BTG2 were determined by qPCR. 48 h after transfection, cells were treated with 10 μM cisplatin or vehicle for 6 h and RNA was prepared. Shown are the results from the triplicate experiments. P value for siRBCK1 versus siControl. siControl were compared to sRBCK1 group; in cisplatin treated samples, siControl was compared to the siRBCK1 group separately. *P < .05; **P < .01; ***P < .001
